
Magna Pharmaceuticals Inc. produces safe, effective drugs for various ailments including allergies, pain, and skin disorders.
Magna Pharmaceuticals Inc. was founded with the core mission of producing safe and effective drugs to address various health issues. The company focuses on developing medications for allergic rhinitis, headaches, backaches, toothaches, and skin-related disorders. Their product line includes treatments for allergies, pain relief, and skincare solutions, such as the MAGNA Hyaluronic Acid Serum. Magna Pharmaceuticals aims to improve the quality of life for its customers by providing reliable and accessible healthcare solutions.
Notable individuals affiliated with Magna Pharmaceuticals include key industry experts and healthcare professionals who contribute to the development and distribution of their products. The company has achieved significant milestones in the pharmaceutical industry by consistently delivering high-quality medications that meet stringent safety standards. Magna Pharmaceuticals has made a substantial impact on the market by addressing common health concerns and providing effective treatments that enhance patient well-being.

Magneceutical Health
magneceutical.com

Zaina Pharma

Manhattan Pharmaceuticals

Bayer Pharmaceuticals
bayer.com

Ivrea Pharmaceuticals

Magdalena Biosciences

Patients' & Consumers' Pharma

Amerigen Pharmaceuticals
amerigenpharma.com

HRA Pharma

Transport Pharmaceuticals

Collegium Pharmaceutical

China PharmaHub

Marillion Pharmaceuticals

Meitheal Pharmaceuticals
meithealpharma.com

Hengrui Therapeutics
Companies similar to Magna Pharmaceuticals include Magneceutical Health, Zaina Pharma, Manhattan Pharmaceuticals and Bayer Pharmaceuticals.
Magna Pharmaceuticals was founded in 1990.
Magna Pharmaceuticals' headquarters is located in Louisville, KY, US.
Magna Pharmaceuticals' most recent funding round was for $1M (USD) in January 2014.
As of Jan 10, 2014, Magna Pharmaceuticals has raised a total of $1M (USD).
Magna Pharmaceuticals has 15 employees as of Feb 5, 2024.